Role of leucine-rich α-2-glycoprotein in Taiwanese patients with inflammatory bowel disease as a predictive biomarker for endoscopic activity

Table 4 Summary of previous and current studies using leucine-rich α-2-glycoprotein to predict inflammatory bowel disease activity

Reference	Endpoints/AUC	Sensitivity/specificity	Cutoff for LRG
Serada et al[6], 2012	UC/clinical CAI
LRG, μg/mL	0.901	84.0%/82.5%	7.21
CRP, mg/dL	0.845	80.0%/80.7%	0.20
Takenaka et al[17], 2023	CD/transmural inflammation
LRG, μg/mL	0.845	67%/90%	14
CRP, mg/dL	0.766	48%/94%	0.03
Asonuma et al[12], 2023	CD/small bowel lesions
LRG, μg/mL	0.77	89.0%/100%	9/16
CRP, mg/dL	0.74	50%/89%	1
Shimoyama et al[16], 2023	IBD/MES > 0 or SES-CD > 2
LRG (UC), μg/mL	0.80	71%/85%	12.7
CRP (UC), mg/dL	0.72	56%/80%	0.14
LRG (CD), μg/mL	0.79	88%/63%	13.3
CRP (CD), mg/dL	0.78	65%/75%	0.46
	IBD/partial Mayo > 0/CDAI > 150
LRG (UC), μg/mL	0.73	69%/73%	12.7
CRP (UC), mg/dL	0.63	66%/53%	0.08
LRG (CD), μg/mL	0.71	67%/71%	22.2
CRP (CD), mg/dL	0.64	64%/68%	0.9
Takada et al[28], 2025	CD/SES-CD > 6
LRG, μg/mL	0.74	70.8%/87.5%	15.5
CRP, mg/dL	0.63	58.3%/71.9%	0.13
Aoyama et al[29], 2025	UC/MES > 1
LRG, μg/mL	0.68	50%/82%	14.8
CRP, mg/dL	0.62	44%/83%	0.21
Ojaghi Shirmard et al[23], 2025	IBD/meta-analysis
LRG, μg/mL	0.82	75.4%/77.3%	-
Current study	IBD/MES ≥ 2 for UC, SES-CD ≥ 6
LRG (UC), μg/mL	0.57	69%/50%	8.1
CRP (UC), mg/dL	0.45	98%/6%	1.01
LRG (CD), μg/mL	0.61	59%/70%	10.8
CRP (CD), mg/dL	0.70	85%/46%	0.08

AUC: Area under the curve; LRG: Leucine-rich α-2-glycoprotein; UC: Ulcerative colitis; CAI: Clinical activity index; CRP: C-reactive protein; CD: Crohn’s disease; IBD: Inflammatory bowel disease; MES: Mayo endoscopic subscore; SES-CD: Simple Endoscopic Score for Crohn’s disease; CDAI: Crohn’s disease activity index.